Summary
Abbott Laboratories reported solid financial results for the third quarter and first nine months of 2009, demonstrating resilience in a challenging economic environment. The company saw an increase in net sales driven by strong performance in its Nutritional Products and Vascular Products segments, alongside growth in international markets. Profitability improved significantly due to a substantial gain from the derecognition of a contingent liability related to the TAP joint venture and a favorable settlement in intellectual property litigation. The company also continued its strategic growth through key acquisitions, notably Advanced Medical Optics (AMO), which bolstered its ophthalmic surgical technology offerings and expanded its R&D capabilities. Despite challenges such as generic competition impacting certain pharmaceutical products and currency headwinds, Abbott maintained a healthy balance sheet with strong operating cash flow. The company also continued its commitment to shareholder returns through dividend payments and share repurchases. Looking ahead, Abbott announced a significant agreement to acquire Solvay's pharmaceuticals business, signaling continued aggressive growth and strategic expansion in key global markets.
Financial Highlights
54 data points| Revenue | $7.76B |
| Cost of Revenue | $3.36B |
| Gross Profit | $4.40B |
| SG&A Expenses | $2.09B |
| Operating Expenses | $6.12B |
| Operating Income | $1.64B |
| Interest Expense | $134.61M |
| Net Income | $1.48B |
| EPS (Basic) | $0.95 |
| EPS (Diluted) | $0.95 |
| Shares Outstanding (Basic) | 1.55B |
| Shares Outstanding (Diluted) | 1.55B |
Key Highlights
- 1Net sales increased by 3.5% to $7.76 billion for the third quarter and 1.8% to $21.97 billion for the first nine months of 2009 compared to the prior year periods.
- 2Diluted Earnings Per Share (EPS) rose to $0.95 for the third quarter and $2.70 for the first nine months of 2009, up from $0.69 and $2.14 respectively in the prior year.
- 3The company recorded a significant gain of $797 million from the derecognition of a contingent liability related to the conclusion of the TAP Pharmaceutical Products Inc. joint venture.
- 4A $287 million gain was recognized from the settlement of intellectual property litigation with Medtronic, Inc.
- 5Abbott completed the acquisition of Advanced Medical Optics (AMO) for approximately $1.4 billion in cash, strengthening its position in eye care technologies.
- 6Operating earnings increased by 17.4% to $1.64 billion for the third quarter and 10.7% to $4.37 billion for the first nine months of 2009.
- 7The company maintained a strong liquidity position with cash and cash equivalents of $4.88 billion at September 30, 2009, and robust operating cash flow.